August 13, 2026 — In a major development for the nation’s public health and rare disease communities, the Health Resources and Services Administration (HRSA) announced the formation of a National Newborn Screening Workgroup. The announcement, which appeared on the agency’s public website ahead of its official publication in the Federal Register on August 12, 2026, marks a crucial turning point for newborn healthcare oversight in the United States.
Under this new initiative, the Association for Public Health Laboratories (APHL) has received a prestigious award from HRSA. The primary objective of this funding is to re-establish a reliable, structured pathway for evaluating and recommending conditions for inclusion on the Recommended Uniform Screening Panel, widely known as the RUSP. Furthermore, the workgroup will serve as a vital forum to discuss and address critical nationwide issues currently impacting newborn screening programs across the country.
The RUSP plays an indispensable role in the United States newborn screening framework. It functions by providing expert, evidence-based guidance to individual state health departments regarding which serious, treatable, and rare conditions should be mandated in state-level screening panels. By establishing a standardized federal benchmark, the RUSP is critical to expanding early detection capabilities and ensuring timely medical intervention. These proactive measures help prevent devastating diagnostic delays, dramatically improve long-term health outcomes, and, most importantly, save children’s lives from conditions that might otherwise go undetected until permanent damage occurs.
The creation of this national workgroup comes at a particularly crucial time following a period of regulatory uncertainty. The longstanding federal process for reviewing and recommending new conditions for the RUSP was abruptly halted following the dissolution of the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) in March 2025. The dismantling of the ACHDNC created significant anxiety and operational uncertainty regarding the future trajectory of the national newborn screening system, leaving advocates, medical professionals, and families searching for a path forward.
Industry experts note that the newly announced workgroup is designed to act as a direct continuation of the vital functions previously managed by the ACHDNC. Specifically, it will pick up the mantle of maintaining the RUSP and restoring robust federal support for the overarching national newborn screening program, bridging the gap left by the previous committee’s dissolution.
Advocacy organizations have been quick to voice their approval of the announcement. The National Organization for Rare Disorders (NORD) has formally recognized the establishment of the National Newborn Screening Stakeholder Workgroup as an essential and highly positive step forward for the national newborn screening infrastructure. For families and individuals affected by rare conditions, the stakes could not be higher. Early detection and prompt medical treatment of serious, rare disorders are critically important for the rare disease community, where every week and month counts in altering a child’s developmental and medical prognosis.
In response to the shifting regulatory landscape over the past year, NORD has been working diligently alongside a broad coalition of stakeholders—including medical researchers, clinicians, public health officials, and family advocates—to advance and preserve the vital efforts previously championed by the Advisory Committee on Heritable Disorders in Newborns and Children. The new partnership with APHL and the backing of HRSA represent a tangible realization of those collaborative efforts, offering renewed hope that the national newborn screening system will continue to evolve, adapt, and protect the country’s youngest and most vulnerable populations.
